Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?

Best Practice and Research: Clinical Haematology

Volumn 24, Issue 4, 2011, Pages 509-514

  Stone, Richard M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; AML; cytometry; FLT3 ITD; minimal residual disease; multiparameter flow (MPF); post remission

Indexed keywords

ARSENIC; CD135 ANTIGEN; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER PREVENTION; CYTOGENETICS; DRUG MEGADOSE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEALTH CARE COST; HIGH RISK PATIENT; INTENSIVE CARE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW CYTOMETRY; MUTATIONAL ANALYSIS; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SURVIVAL TIME;

EID: 82355161561     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2011.09.006     Document Type: Review

References (16)

1. P. Hokland, and H.B. Ommen Towards individualized follow-up in adult acute myeloid leukemia in remission Blood 117 2011 2577 2584
2. G. Marcucci, T. Haferlach, and H. Dohner Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications J Clin Oncol 29 2011 475 486
3. G. Basso, M. Veltroni, and M.G. Valsecchi Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow J Clin Oncol 27 2009 5168 5174
4. J.E. Rubnitz, H. Inaba, and G. Dahl Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial Lancet Onc 11 2011 543
5. J.F. San Miguel, M.G. Vidriales, and C. Lopez-Berges Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to post induction treatment stratification Blood 98 2001 1746 1751
6. D. Cilloni, A. Renneville, and F. Hermitte Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet Study J Clin Oncol 27 2009 5195 5201
7. S.R. McCormick, M.J. McCormick, and P.S. Grutkoski FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations including cuplike blast morphology Arch Patho Lab Med 8 2010 1143 1151
8. F. Buccisano, L. Maurillo, and A. Spagnoli Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia Blood 116 2010 2295 2303
9. G. Nucifora, R.A. Larson, and J.D. Rowley Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission Blood 82 1993 712 715 (Pubitemid 23221647)
10. T. Miyamote, K. Nagafuji, and M. Harada Significance of quantitative analysis of AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia Leuk Lymphoma 25 1-2 1997 69 75 (Pubitemid 27165652)
11. F. Morschhauser, J.M. Cayuela, and S. Martini Evaluation of minimal residual disease using reverse transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients J Clin Oncol 18 2000 788 794 (Pubitemid 30106609)
12. A. Corbacioglu, C. Scholl, and R. Schlenk Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia J Clin Oncol 28 2010 3724 3729
13. J. Krauter, K. Gorlich, and O. Ottmann Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias J Clin Oncol 21 2003 4413 4422 (Pubitemid 46621819)
14. G. Meloni, D. Diverio, and M. Vignetti Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene Blood 90 1997 1321 1325 (Pubitemid 27314172)
15. D. Grimwade, J.V. Jovanovic, and R.K. Hills Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy J Clin Oncol 27 2009 3650 3658
16. R.B. Walter, R.A. Gooley, and B.L. Wood Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia J Clin Oncol 29 2011 1190 1197